Arjun Kanwal

Arjun Kanwal

Auto-generated profile, based on publicly available information

Arjun Kanwal

Department of Cardiology, Westchester Medical Center, Valhalla, NY, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2020 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
FTFadi Taza
Fadi Taza
MZMary Zulty
Mary Zulty
AKArjun Kanwal
Arjun Kanwal
DGDaniel Grove
Daniel Grove
COVID-19 became a global pandemic in early 2020. While well known for its pulmonary manifestations, the virus also has a number of cardiac manifestations as well. Takotsubo syndrome has scarcely been reported in patients with COVID-19, but it is possible that the cytokine storm associated with the infection can trigger Takotsubo syndrome in patients with underlying risk factors for Takotsubo (emotional distress, physical distress, history of psychiatric disorders).

8 October 2021 in Journal of Cardiovascular Computed Tomography
Verified
Journal Article
Closed access
KGKeva Garg
Keva Garg
TPToral R. Patel
Toral R. Patel
AKArjun Kanwal
Arjun Kanwal
TVTodd C. Villines
Todd C. Villines
NANiti R. Aggarwal
Niti R. Aggarwal
GSGarima Sharma
Garima Sharma

24 January 2020 in American Journal of Case Reports
Verified
Journal Article
Open access
AKArjun Kanwal
Arjun Kanwal
DADimitrios Avgeropoulos
Dimitrios Avgeropoulos
JKJason G. Kaplan
Jason G. Kaplan
ASAditya Saini
Aditya Saini
BACKGROUND Acute bacterial pericarditis is rare, and the incidence numbers have been declining in the modern antibiotic era. Purulent bacterial pericarditis is a fatal disease in which mortality rates can reach 100% if left untreated. CASE REPORT We present a case of primary purulent bacterial pericarditis with polymicrobial growth including Micromonas micro, Prevotella intermedia and Fusobacterium species, all of which are anaerobic flora of the oral cavity. Constant re-accumulation of the purulent pericardial effusion led the patient to have recurrent echocardiographic and clinical cardiac tamponade requiring recurrent pericardiocentesis' and eventually a pericardial window. CONCLUSIONS Although rare, bacterial pericarditis has been noted to lead to clinical and echocardiographic tamponade. Early diagnosis and treatment are necessary for improving clinical outcomes. It is important to have a suspicion for purulent pericarditis, due to its high level of mortality, in patients who present with non-specific symptoms and pleuritic chest pain.

4 June 2023 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Closed access
ARAkiva Rosenzveig
Akiva Rosenzveig
NGNeil Garg
Neil Garg
SRShiavax J. Rao
Shiavax J. Rao
AKAmreen K. Kanwal
Amreen K. Kanwal
AKArjun Kanwal
Arjun Kanwal
MMMatthew W. Martinez
Matthew W. Martinez

3 May 2020 in Journal of Community Hospital Internal Medicine Perspectives
Verified
Journal Article
Open access
FTFadi Taza
Fadi Taza
AKArjun Kanwal
Arjun Kanwal
MZMary Zulty
Mary Zulty
SMSadaf Mustafa
Sadaf Mustafa
Rhabdomyosarcoma is an aggressive malignant soft-tissue sarcoma that develop from undifferentiated mesenchymal cells. Less than 1% of all adult solid malignant cancers are sarcomas, and RMSs represent less than 2-5% of adult sarcomas. RMS is divided into three main subtypes: Embryonal, alveolar and pleomorphic RMS (PRMS). Most common subtype in adults is PRMS. Most common primary sites are extremities, trunk wall, and genitourinary organs. Metastasis are often found at diagnosis. 5-year overall survival rates were reported in the Surveillance, Epidemiology, and End Results database (SEER) to be 63% for pediatric patients and 27% for adults. Given the rarity of the adult PRMS, variation in its clinical presentation, characteristics of the tumor itself and the prognosis; there are very limited data available to guide the management of adults with PRMS. Herein we present a case report of pleomorphic rhabdomyosarcoma of the right thigh in a 60-year-old male who achieved a long-term survival (30 months) which was accomplished by multimodality treatment including surgery, radiotherapy, and chemotherapy.

1 January 2023 in Hospital Practice
Verified
Journal Article
Closed access
SRShiavax J. Rao
Shiavax J. Rao
SIShaikh Bilal Ali Iqbal
Shaikh Bilal Ali Iqbal
AKArjun S. Kanwal
Arjun S. Kanwal
Wilbert AronowWilbert Aronow
Wilbert Aronow
SNSrihari S. Naidu
Srihari S. Naidu
Hypertrophic cardiomyopathy (HCM) is an autosomal dominant inherited condition defined by left ventricular wall thickness greater than 15 mm in the absence of other conditions that could explain that degree of hypertrophy. Obstructive HCM associated with left ventricular outflow tract obstruction is defined by an intraventricular systolic pressure gradient greater than or equal to 30 mm Hg. Over the past couple of decades, there has been an expansion of both invasive and pharmacotherapeutic options for patients with HCM, with recent guidelines calling for a melody of invasive and non-invasive treatment strategies. There are several invasive therapies including proven therapies such as alcohol septal ablation and septal myectomy. Novel invasive therapies such as MitraClip, radiofrequency septal ablation and SESAME procedure have more recently been promoted. Pharmacological therapy has also dramatically evolved and includes conventional medications such as beta-blockers, calcium channel blockers, and disopyramide. Mavacamten, a novel cardiac myosin inhibitor, may significantly change management. Other myosin inhibitors and modulators are also being developed and tested in large clinical trials. Given significant phenotypical variability in patients with HCM, clinical management can be challenging, and often requires an individualized approach with a combination of invasive and non-invasive options.